MEETINGS - Conference on New Approaches for Compliance after FDA Modernisation Act 1997 (UK) May 1998:
This article was originally published in Clinica
New Approaches for Compliance after the FDA Modernisation Act 1997 will be the subject of an IBC conference in London on May 18. Issues to be addressed include what effect the reforms will have on the product review system; how the FDA will evaluate exemption requests; changes to labelling and promotion of medical devices; the impact the new law will have on post marketing activities; and possible implications for mutual recognition agreements and global harmonisation. For more information contact IBC in the UK. Tel: +44 171 453 5492. Fax: +44 171 453 2739.
You may also be interested in...
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.